Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • CKD in children: a range of etiologies
  • Genomic imbalance: a diagnostic tool for CKD?
  • Challenges for genomic technologies in the clinic
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Free access | 10.1172/JCI81509

Idiopathic pediatric chronic kidney disease: can genomic technology crack the case?

Martin R. Pollak

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Address correspondence to: Martin R. Pollak, 99 Brookline Ave., Boston, Massachusetts 02214, USA. Phone: 617.667.0461; E-mail: mpollak@bidmc.harvard.edu.

Find articles by Pollak, M. in: JCI | PubMed | Google Scholar

Published April 20, 2015 - More info

Published in Volume 125, Issue 5 on May 1, 2015
J Clin Invest. 2015;125(5):1799–1800. https://doi.org/10.1172/JCI81509.
Copyright © 2015, American Society for Clinical Investigation
Published April 20, 2015 - Version history
View PDF

Related article:

Genomic imbalances in pediatric patients with chronic kidney disease
Miguel Verbitsky, … , Craig S. Wong, Ali G. Gharavi
Miguel Verbitsky, … , Craig S. Wong, Ali G. Gharavi
Clinical Medicine Genetics Nephrology

Genomic imbalances in pediatric patients with chronic kidney disease

  • Text
  • PDF
Abstract

BACKGROUND. There is frequent uncertainty in the identification of specific etiologies of chronic kidney disease (CKD) in children. Recent studies indicate that chromosomal microarrays can identify rare genomic imbalances that can clarify the etiology of neurodevelopmental and cardiac disorders in children; however, the contribution of unsuspected genomic imbalance to the incidence of pediatric CKD is unknown.

METHODS. We performed chromosomal microarrays to detect genomic imbalances in children enrolled in the Chronic Kidney Disease in Children (CKiD) prospective cohort study, a longitudinal prospective multiethnic observational study of North American children with mild to moderate CKD. Patients with clinically detectable syndromic disease were excluded from evaluation. We compared 419 unrelated children enrolled in CKiD to multiethnic cohorts of 21,575 children and adults that had undergone microarray genotyping for studies unrelated to CKD.

RESULTS. We identified diagnostic copy number disorders in 31 children with CKD (7.4% of the cohort). We detected 10 known pathogenic genomic disorders, including the 17q12 deletion HNF1 homeobox B (HNF1B) and triple X syndromes in 19 of 419 unrelated CKiD cases as compared with 98 of 21,575 control individuals (OR 10.8, P = 6.1 × 10–20). In an additional 12 CKiD cases, we identified 12 likely pathogenic genomic imbalances that would be considered reportable in a clinical setting. These genomic imbalances were evenly distributed among patients diagnosed with congenital and noncongenital forms of CKD. In the vast majority of these cases, the genomic lesion was unsuspected based on the clinical assessment and either reclassified the disease or provided information that might have triggered additional clinical care, such as evaluation for metabolic or neuropsychiatric disease.

CONCLUSION. A substantial proportion of children with CKD have an unsuspected genomic imbalance, suggesting genomic disorders as a risk factor for common forms of pediatric nephropathy. Detection of pathogenic imbalances has practical implications for personalized diagnosis and health monitoring in this population.

TRIAL REGISTRATION. ClinicalTrials.gov NCT00327860.

FUNDING. This work was supported by the NIH, the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute.

Authors

Miguel Verbitsky, Simone Sanna-Cherchi, David A. Fasel, Brynn Levy, Krzysztof Kiryluk, Matthias Wuttke, Alison G. Abraham, Frederick Kaskel, Anna Köttgen, Bradley A. Warady, Susan L. Furth, Craig S. Wong, Ali G. Gharavi

×

Abstract

In children, chronic kidney disease (CKD) that results from structural abnormalities and glomerular injury is readily diagnosed; however, most cases of pediatric CKD are of unknown etiology. In this issue of the JCI, Verbitsky and colleagues used chromosomal microarrays to evaluate genomic variation in children with CKD. Compared with control individuals, a substantial proportion of children with idiopathic CKD had clearly identifiable genomic imbalances. Moreover, in some cases, detailed analysis of these imbalances identified pathogenic alterations that were unsuspected based on clinical presentation. The results of this study support genome-wide evaluation for pediatric cases of CKD; however, more work will need to be done before such an approach is widely available in the clinic.

CKD in children: a range of etiologies

Chronic kidney disease (CKD) is a set of conditions characterized by gradually declining kidney function. Therapies for CKD are largely aimed at preventing progression into end-stage renal disease (ESRD). Therefore, early detection is of the utmost importance. In the US, diabetic nephropathy, vascular disease, and hypertension-attributed nephropathy are among the leading forms of CKD in adults (1). In children, the spectrum of etiologies that underlie CKD is quite different. Studies of children that have received kidney transplants for CKD that progressed to ESRD indicate that structural kidney disease accounts for roughly 30% to 40% of cases, primary glomerular injury accounts for approximately of 5% to 25% of cases (depending on age), and the remainder of cases are due to other or indeterminate causes (2).

Similar to treatment for adult cases of CKD, current therapies for established CKD in children are largely aimed at reducing the many serious complications of kidney disease and slowing the progression of CKD to ESRD. Once CKD has progressed to ESRD, some form of renal replacement therapy, such as kidney transplant, hemodialysis, or peritoneal dialysis, is required for the lifetime of the individual. Because of the high morbidity associated with pediatric CKD, the best “therapy” is preventing the initial cause of disease from progressing to a chronic, irreversible state; however, such an early diagnosis or risk determination in children is often not possible.

As many cases of childhood CKD are of unknown etiology, several questions arise for the clinicians that see these patients. What studies should be included in the diagnostic evaluation of a child with idiopathic CKD? As some forms of CKD result from genetic mutations, is there a role for genetic testing in the evaluation process for children with CKD? Precision medicine, the notion that specific causes and modifiers of disease should be identified in every patient, has been touted as the future of medicine. Will new technologies allow us to pinpoint those causes that are genetic in nature? Can useful conclusions be made about individual patients, or are genetic tools best left in the research arena as part of efforts to identify rare and common contributors to disease?

Genomic imbalance: a diagnostic tool for CKD?

A previous study by Sanna-Cherchi et al. examined the presence of duplicated or absent chromosomal segments, so-called copy number variants (CNVs), in a cohort of individuals with renal hypodysplasia, which encompasses several congenital malformations of the kidney (3). Compared with control individuals, patients with renal hypodysplasia exhibited an altered distribution of large CNVs that skewed toward larger-sized alterations. Moreover, a marked number of these alterations disrupted gene loci, compared with CNVs that were observed in control subjects.

In this issue, Verbitsky et al. (4) used a chromosomal microarray approach to evaluate the presence of CNVs in DNA from 419 children with CKD, but not syndromic disease. The subjects in this study were drawn from the Chronic Kidney Disease in Children (CKiD) cohort study, a prospective epidemiologic study designed to create a better understanding of CKD risk factors as well as the impact of declining kidney function on other aspects of health (5). Verbitsky and colleagues determined that many of these young individuals with CKD have a large excess of genomic imbalances, an observation that was not suspected after standard clinical evaluation. The presence of large gene-altering CNVs was much more common in CKiD subjects than in controls (37.7% versus 23.4%). An increased burden of genetic alterations does not by itself allow one to make a genetic diagnosis for CKD in an individual; however, detailed annotation of the identified CNVs allowed for precise genetic diagnoses in a substantial number of cases. Specifically, 31 of the 419 individuals had a known or likely disease-causing genomic imbalance. As Verbitsky and colleagues illustrate, in a substantial number of these cases, the specific genetic alteration identified would be expected to lead to targeted and personalized recommendations for ongoing clinical care.

Given the rather broad and nonspecific nature of the CKD-associated phenotypes, the observation that chromosomal microarray analyses yielded informative results for individual subjects is particularly important. For any clinical test, its utility for refining a diagnosis and guiding therapy should be considered. There is little value in test results if the diagnosis is already clear before testing. If the prior probability of a positive test is so low that a false positive result is more likely than a true positive (e.g., a test result reporting, say, an apparently pathogenic polycystic kidney disease gene mutation in a healthy 80 year old with no kidney cysts), then that test is also of little value. Thus, the observation by Verbitsky and colleagues that in a collection of children with CKD, evaluation for the presence of CNVs yields a significant amount of clinically actionable information is exciting and offers a potential diagnostic test for children with idiopathic CKD.

Challenges for genomic technologies in the clinic

Should such comprehensive, genome-wide analyses now be performed in all children with CKD, or should this testing be limited to selected subsets of patients? Moreover, what technologies should be used for such evaluation, and what sort of genetic alterations should be assessed? A strong case can already be made for looking for point mutations in genes known to underlie steroid-resistant nephrotic syndrome in affected children. Therapeutic decisions and recommendation for kidney transplantation may be altered by the knowledge gained from such testing (6). But what about in the case of idiopathic CKD, in which a glomerular etiology seems less likely and the presence of gene-disrupting CNVs may underlie disease? The results of the Verbitsky paper certainly provide compelling data and suggest that clinically relevant CNVs may be present in a nontrivial fraction of children with CKD.

Many of the children in the CKiD study fall into the broad category of patients with congenital abnormality of the kidney and urinary tract (CAKUT), which refers to a group of disorders that includes ureteropelvic junction obstruction, reflux nephropathy, renal hypodysplasia, and obstruction at the ureteropelvic junction. CNVs are not the only cause of CAKUT, as point mutations in a number of genes can cause CAKUT and consequent CKD (7, 8). A comprehensive analysis of childhood CKD should likely include analyses of the sequence of these genes as well as an assessment of CNVs. Unfortunately, clinical implementation of the types of genetic analysis required to detect these abnormalities is not simple. Of course, the cost of these tests and the willingness of insurance companies to cover such analysis are distressingly complex and nonuniform across the US. The technical cost associated with performing a microarray-based analysis of patients, such as the one performed by Verbitsky et al., is no longer exorbitant. The larger obstacle for wide-scale application of this technology is the ability to perform proper quality control, analysis, and interpretation of the large data set generated. Moreover, appropriate counseling based on the results will be a potential stumbling block for this technology.

Genomic technology is rapidly changing. Whole-genome sequencing continues to become increasingly cheap and accurate. In the right setting, genome analysis not only allows for detection of structural changes, but also can identify disease-influencing and disease-causing single nucleotide changes. Until the issues of quality control and reliable data set analysis can be resolved, genome technology will not be widely available as a diagnostic tool in the clinic for CKD and other idiopathies. Nevertheless, the study by Verbitsky and colleagues suggests that for the broadly defined condition CKD, a wisely applied genetic analysis has potential to add to the precision of diagnosis and alter treatment for the better.

Footnotes

Conflict of interest: The author has declared that no conflict of interest exists.

Reference information: J Clin Invest. 2015;125(5):1799–1800. doi:10.1172/JCI81509.

See the related article at Genomic imbalances in pediatric patients with chronic kidney disease.

References
  1. United States Renal Data System. 2014 Annual Data Report: An overview of the epidemiology of kidney disease in the United States. Bethesda, Maryland, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
  2. Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplantat. 2013;17(2):149–157.
    View this article via: PubMed CrossRef Google Scholar
  3. Sanna-Cherchi S, et al. Copy-number disorders are a common cause of congenital kidney malformations. Am J Hum Genet. 2012;91(6):987–997.
    View this article via: PubMed CrossRef Google Scholar
  4. Verbitsky M, et al. Genomic imbalances in pediatric patients with chronic kidney disease. J Clin Invest. 2015;125(5):2171–2178.
    View this article via: JCI Google Scholar
  5. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis. 2012;60(6):1002–1011.
    View this article via: PubMed CrossRef Google Scholar
  6. Sadowski CE, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. [published online ahead of print October 27, 2014]. J Am Soc Nephrol. doi:10.1681/ASN.2014050489.
    View this article via: PubMed CrossRef Google Scholar
  7. Vivante A, Kohl S, Hwang DY, Dworschak GC, Hildebrandt F. Single-gene causes of congenital anomalies of the kidney and urinary tract (CAKUT) in humans. Pediatr Nephrol. 2014;29(4):695–704.
    View this article via: PubMed CrossRef Google Scholar
  8. Hwang DY, et al. Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract. Kidney Int. 2014;85(6):1429–1433.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (April 20, 2015): No description
  • Version 2 (May 1, 2015): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • CKD in children: a range of etiologies
  • Genomic imbalance: a diagnostic tool for CKD?
  • Challenges for genomic technologies in the clinic
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts